RAPID DEVELOPMENT OF A VAXFECTIN®-ADJUVANTED DNA VACCINE ENCODING PANDEMIC SWINE-ORIGIN INFLUENZA A VIRUS (H1N1) HEMAGGLUTININ

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gene Therapy and Regulation

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1142/S1568558609000084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.

  2009cited by this paper
• Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

  2009cited by this paper
• DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial.

  2009cited by this paper
• Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong.

  2009cited by this paper
• Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

  2009cited by this paper
• Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

  2008cited by this paper
• Use of Vaxfectin Adjuvant with DNA Vaccine Encoding the Measles Virus Hemagglutinin and Fusion Proteins Protects Juvenile and Infant Rhesus Macaques against Measles Virus

  2008cited by this paper
• A TaqMan® Reverse Transcription Polymerase Chain Reaction (RT-PCR) In Vitro Potency Assay for Plasmid-based Vaccine Products

  2008cited by this paper
• Vaccination with Polymerase Chain Reaction-Generated Linear Expression Cassettes Protects Mice Against Lethal Influenza A Challenge

  2007cited by this paper
• Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

  2007cited by this paper
• Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.

  2006cited by this paper
• Genetic Vaccines and Therapy

  2006cited by this paper
• Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.

  2006cited by this paper
• Epidermal DNA vaccine for influenza is immunogenic in humans.

  2006cited by this paper
• Evaluation of Genetic Immunization Adjuvants to Improve the Effectiveness of a Human Immunodeficiency Virus Type 2 (HIV-2) Envelope DNA Vaccine

  2004cited by this paper
• Multiple Epitopes in the Murine Cytomegalovirus Early Gene Product M84 Are Efficiently Presented in Infected Primary Macrophages and Contribute to Strong CD8+-T-Lymphocyte Responses and Protection following DNA Immunization

  2004cited by this paper
• Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection.

  2004cited by this paper
• Enhancing Effect of Vaxfectin on the Ability of a Japanese Encephalitis DNA Vaccine to Induce Neutralizing Antibody in Mice

  2003cited by this paper
• Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids

  2002cited by this paper
• Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

  2001cited by this paper
• Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.

  2001cited by this paper

• Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines

  2010cites this paper